Related Experiment Video

Updated: Jul 4, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

Reducing CVD risk - integration of clinical and laboratory criteria

David P Tognarini1, David R Sullivan, David W Thomas

  • 1Aesir Medical Research, Victoria, Australia.

Australian Family Physician
|June 5, 2008
PubMed

Insights

New Australian guidelines align lipid management and therapy subsidies, focusing on low-density lipoprotein cholesterol. This aims to clarify treatment for patients and clinicians, despite potential initial confusion with updated recommendations.

Area of Science:

  • Cardiology
  • Clinical Pathology
  • Pharmacoeconomics

Background:

  • Recent updates to National Heart Foundation of Australia (NHFA) Lipid Management Guidelines and Pharmaceutical Benefits Scheme (PBS) criteria for lipid-lowering therapy have increased alignment.
  • NHFA guidelines now emphasize low-density lipoprotein cholesterol (LDL-C) over total cholesterol, a shift supported by literature but potentially confusing for patients and clinicians.

Purpose of the Study:

  • Summarize pathology reporting changes following the Australian Pathology Lipid Interest Group's review of NHFA guidelines.
  • Compare current PBS criteria for lipid-lowering therapy subsidies with NHFA high-risk categories and treatment targets.
  • Provide a treatment algorithm based on PBS criteria, integrating risk factors and lipid levels.

Main Methods:

  • Comparative analysis of NHFA guidelines and PBS criteria.
  • Review of pathology reporting standards.
  • Development of a clinical algorithm for lipid management.

Main Results:

  • Greater alignment between NHFA guidelines and PBS criteria for lipid-lowering therapy.
  • Potential for confusion regarding LDL-C focus versus total cholesterol.
  • An integrated algorithm for treatment decisions based on PBS criteria.

Conclusions:

  • Pathology testing is crucial for risk assessment in patients.
  • Clinicians must determine absolute cardiovascular risk using comprehensive clinical information.
  • Final treatment decisions for lipid management rest with the clinician.
Abstract

Related Concept Videos

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...